Johnson and Johnson, Takeda and Evotec joined the Alzheimer's Alliance

dementia alliance has expanded to Johnson and Johnson Innovations, Takeda and Evotec, which have joined a unique collaboration on dementia drug discovery in the charity industry of 9.5 million pounds.The new phase of the Dementia Alliance sees the UK's leading dementia research charity, the Alzheimer's Research Centre, join forces to promote the discovery of dementia drugs. The new name will be joined by existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD.The Dementia Alliance is a leading partner program that provides funding, industry expertise and project management resources to academic researchers to use new drug targets to treat neurodegenerative diseases that cause dementia.Currently, it supports seven ground-breaking projects, many more are under way, and is currently accepting applications for innovative dementia targets, with a rolling deadline for expressions of interest every three months. Successful projects could then be considered to license industrial partners to facilitate the entry of new therapies into clinical practice.Sir Simon Lovestone, head of neurodegenerative diseases at Jensen Research and Development, said: "We are delighted to be working together as part of the Dementia Alliance and we believe this is an exciting way to identify new targets for drug discovery for neurodegenerative diseases and to help patients with central nervous system diseases around the world. Diseasesthe Alzheimer's Alliance include Alzheimer's disease, Louis's dementia, frontal lobe dementia, and Parkinson's disease and Huntington's disease. (China Pharmaceutical 123 Network)